Second close for NeoMed life science fund

NeoMed Management has reached a second closing of its fourth fund NeoMed Innovation IV LP, a Jersey domiciled healthcare and life sciences venture capital fund, bringing total committed capital to E70m.

Investors in the fund include fund-of-funds, institutional and private investors based in the UK, Sweden, Norway, Saudi Arabia and Switzerland. The fund has a target of around E100m and is aiming for a final close at the end of the year.

NeoMed Management is a venture capital firm focused on the international healthcare and life sciences industry working from offices in Oslo, Geneva and New York.

The fund will continue NeoMed’s focus on investments in emerging healthcare and life sciences companies in continental Europe, Scandinavia and to a lesser extent in the UK and the US.

NeoMed’s recent portfolio investments include Axovan, Kuros BioSurgery and Thommen Medical in Switzerland, Clavis Pharma in Norway, Paion in Germany. NeoMed’s US investments are mostly syndicated investments with leading local venture capitalists and include Aderis, Pharmion, Volcano Therapeutics and Xanthus.

Erik Amble, founding partner of NeoMed Management said: “We are pleased to be on track establishing our fourth fund with an international, institutional investor base. It reflects NeoMed Management’s investment approach developing innovative companies with an international perspective and strengthens NeoMed’s position as a leading European based venture capital firm specialised in the healthcare and life sciences industry.”